Singapore medical device maker Biosensors lowers its expectations for the year on a lackluster market and delays in Japanese growth.
Singapore-based stent-maker Biosensors International (SGX:B20) lowered its full-year sales outlook, reporting softness in the stent market, pricing pressures and delays in anticipated royalty growth in Japan.
The company’s profits sank by 60% during the 3 months ended September 30, the company said, even as sales increased 4%.
